OncRef

Clinical Trial: NCT04612751

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-07-27

Study Overview

Brief Summary

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Official Title

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

Conditions

Advanced or Metastatic NSCLC

Intervention / Treatment

  • Drug: Datopotamab deruxtecan
  • Drug: Durvalumab
  • Drug: Carboplatin
  • Drug: AZD2936
  • Drug: MEDI5752
  • Drug: AZD7789

Other Study ID Numbers

  • D926FC00001
  • 2023-505992-54-00
  • 2021-000274-28
  • 2023

Start Date (Actual)

2021-02-02

Primary Completion Date (Actual)

2026-05-04

Study Completion Date (Estimated)

2027-05-04

Enrollment (Actual)

155

Study Type

Interventional

Phase

Phase 1